A 66-year-old woman had massive bilateral adrenal macronodular hyperplasia, found incidentally on an abdominal ultrasonogram. Her plasma ACTH and serum cortisol levels were normal, but they were not suppressed by low-dose dexamethasone. The patient did not exhibit any typical signs or symptoms of Cushing's disease. MRI showed no evidence of a tumor in the pituitary gland. A diagnosis of preclinical Cushing's disease was made, and she was treated with 11-hydroxylase inhibitor metyrapone. As the dose of metyrapone was increased, plasma ACTH levels gradually increased. After three years of treatment, she developed moon-face. Her plasma ACTH and serum cortisol concentrations were at their highest levels. A pituitary microadenoma was detected by MRI, whose source of ACTH was demonstrated by the definite step-up of central/peripheral ratio of ACTH obtained by cavernous sinus sampling. Overt Cushing's disease was diagnosed, and a pituitary tumor was removed by transsphenoidal surgery. In conclusion, the clinically and endocrinologically overt Cushing's disease characterized by macronodular adrenal hyperplasia was converted from a preclinical form. This case offers some insight into the clinical and biological features of preclinical Cushing's disease.
ACTH-independent Cushing's syndrome that lacks typical clinical features is referred to as preclinical Cushing's syndrome [1] . Preclinical Cushing's syndrome is often diagnosed in patients with adrenal incidentaloma, but preclinical ACTH-dependent Cushing's disease secondary to pituitary corticotroph adenomas (Cushing's disease) are rare [2] [3] [4] [5] . Cushing's disease usually leads to adrenal hyperplasia due to chronic ACTH hypersecretion [6, 7] . However, 10% to 40% of patients with Cushing's disease have bilateral adrenocortical hyperplasia associated with one or more nodules, even up to seven cm in diameter [8, 9] . Such macronodular hyperplasia tends to occur more often in older patients [9, 10] and in patients with longstanding Cushing's disease than in those with classical clinical features of Cushing's syndrome.
Several questions concerning preclinical Cushing's disease remain to be answered. The first question is whether preclinical Cushing's disease has adrenal shape changes as overt Cushing's disease, and the second question is whether preclinical Cushing's disease is converted clinically and endocrinologically to overt Cushing's disease overtime.
We report a case of preclinical Cushing's disease in a patient with massive macronodular adrenal hyperplasia. After three years of treatment with metyrapone, the patient developed overt Cushing's disease.
Case Report
A woman was diagnosed with diabetes mellitus at the age of 44 years. She started to receive an oral hypoglycemic drug at 46 years old, and then switched to insulin injection at 52 years old. At 59 years of age, she had hypertension, and was given antihypertensive drug. When she was 62 years old, she became blind as a result of diabetic retinopathy. Two years later, at the age of 64, she was referred to our hospital because an ultrasonogram incidentally revealed bilateral enlargement of the adrenal glands. The patient was admitted for further examination of possible adrenal disorders. On admission, there were no typical clinical manifestations of Cushing's syndrome. The basal hormonal data are shown in Table 1 . Basal plasma ACTH and serum cortisol levels were normal, but urinary excretions of free cortisol and 17-OHCS were high. Diurnal rhythm of ACTH and cortisol secretion was maintained. GH level was normal, but IGF-I was high. The results of endocrine dynamics are shown in Table 2 . CRH test yielded normal ACTH and cortisol responses, and an overnight dexamethasone suppression test showed no Patient discontinued metyrapone therapy UFC = urinary free cortisol; 17-KS = 17-ketosteroid; 17-OHCS = 17-hydroxycorticosteroid; DHEA-S = dehydroepiandrosterone; IGF-I = insulin growth factor-I; PRA = plasma renin activity; PAC = plasma aldosterone concentration With the lack of typical features for Cushing's disease, preclinical Cushing's disease with adrenal hyperplasia (Fig. 1A) was suggested; however, magnetic resonance imaging (MRI) ( Fig. 2A) failed to demonstrate any pituitary adenoma. The patient's serum cortisol level was slightly high and because the patient declined further examination, we treated her with 11-hydroxylase inhibitor methyrapone in the outpatient clinic. The dosage of metyrapone was gradually increased up to 1250 mg to maintain the normal level of cortisol; the basal levels of ACTH, urinary free cortisol (UFC), 17-OHCS, and 17-KS gradually increased with the dose of methyrapone. At the highest dose (1250 mg of metyrapone), plasma ACTH and serum cortisol levels rose up to 401 pg/ml and to 22.3 µg/dl, respectively. The patient was admitted for a reevaluation after three years of metyrapone therapy. Her clinical course is shown in Fig. 3 .
On the second admission, the patient's body height was 154.4 cm, body weight 59.2 kg, and the body mass index (BMI) 24.9 kg/m 2 . Her blood pressure was 132/ 72 mmHg on amlodipine 2.5 mg daily. The patient exhibited moon-face, but had no other features suggestive of Cushing's syndrome. The peak fasting plasma glu- cose and HbA 1c levels on insulin therapy were 249 mg/ dl and 5.9% respectively. Plasma ACTH and serum cortisol, UFC, 17-KS, 17-OHCS (Table 1 ), and IGF-1 level were all elevated. The diurnal rhythm of ACTH and cortisol secretion had been completely lost. A CRH provocation (100 µg, iv) test at the second admission showed greater ACTH and cortisol responses than those of the first admission (Table 2) . Plasma ACTH and serum cortisol levels did not increase in response to the administration of desmopressin (4 µg). Serum cortisol was not suppressed by low-dose (1 mg) dexamethasone, but was suppressed by a high-dose (8 mg) dexamethoasone ( Table 2) . CT of the abdomen showed bilateral enlargement of the adrenal glands (right: 4 × 1.5 cm; left: 5 × 3 cm), with ( Fig. 1B-1 ) or without contrast medium enhancement (Fig. 1B-2) , the sizes of these adrenal tumors increased more than that of the first admission (Fig. 1A) . These findings confirmed the diagnosis of overt Cushing's disease. Brain dynamic MRI showed a microadenoma in the anterior pituitary gland (Fig. 2B) . Box MRI of a pituitary showed a mass lesion (5 mm in diameter) on the right side (Fig. 2C) . Selective catheterization and blood sampling in the inferior petrosal sinus and cavernous sinus were performed to identify the site of ACTH hypersecretion (Table 3) . A significant step-up of central-to-peripheral (C/P) ACTH ratio (2.5) was noted under a basal state; CRH stimulation test was not performed. A right-to -left gradient was observed at the inferior cavernous sinus. These findings suggested a corticotroph adenoma located on the right side and at the inferior pole of the pituitary. Pituitary adenomectomy was performed by a transsphenoidal approach, and the tumor was confirmed on the right side of the pituitary. Immmunohistochemical study using anti-ACTH demonstrated that the tumor produced ACTH-like immunoreactivity (Fig. 4) ; staining of other pituitary hormones was negative. Both plasma ACTH and serum cortisol levels failed to decrease after surgery, nor did her blood pressure or plasma glucose levels. MRI sug- gested a residual tumor on the right side of the pituitary, and a stereotaxic radiosurgery by a gamma knife is currently considered as an adjunctive therapy.
Discussion
Our patient did not initially have any typical manifestations of Cushing's disease, and the basal plasma ACTH and serum cortisol levels were within their normal ranges. She had been treated for hypertension and diabetes mellitus, but these diseases were not helpful for diagnosing Cushing's disease. Our case was compatible with preclinical Cushing's disease. Preclinical Cushing's disease has not been reported as often as preclinical Cushing's syndrome. Preclinical Cushing's disease has been diagnosed by several researchers based on their independent criteria [2, 3, 5, 11] . The following endocrinological findings may be considered as a framework of the diagnostic criteria: 1) lack of clinical features suggestive of Cushing's disease, 2) evidence of autonomous or abnormal secretion of ACTH, such as lack of diurnal rhythms of ACTH and cortisol secretion, normal or high plasma DHEA-S levels and urinary excretion of free cortisol, incomplete suppression of ACTH and cortisol by a low-dose dexamethasone suppression test, normal or exaggerated response of plasma ACTH levels to CRH, and/or response of plasma ACTH levels to desmopressin, and 3) presence of a pituitary adenoma.
The most characteristic feature of preclinical Cushing's disease in our patient was the massive macronodular adrenal hyperplasia. Chronic excess ACTH can cause adrenal hyperplasia [7, 9, [12] [13] [14] , but an adrenal hyperplasia as large as that of our patient in preclinical Cushing's disease has never been reported before. It is interesting that preclinical Cushing's disease was found incidentally with adrenal hyperplasia. Moreover, bilateral adrenal hyperplasia was enlarged during the long-term administration of metyrapone. Adrenal hyperplasia may occur in patients with low to normal plasma ACTH levels when a corticotroph adenoma secretes large amounts of N-terminal pro-opiomelanocortin (POMC) peptides [6, 15] , and in patients with high IGF-I levels [16] [17] [18] [19] [20] . We did not measure plasma N-terminal POMC peptide levels in our patient, but plasma IGF-I level was slightly elevated. Since immunostaining GH of the resected pituitary adenoma was negative, the pituitary adenoma appeared to secrete ACTH alone but not GH. It remains unclear whether preclinical Cushing's disease progresses to the clinically overt form over time or remains in the preclinical form. In our patient, the preclinical form was converted to overt Cushing's disease after three years. The patient had a moon face and high circulating levels of ACTH and cortisol. Whether metyrapone treatment have changed and modified the natural course of the disease remains unknown. We were unable to clarify the effect of metyrapone on the progression of this disease based on this observational case report. The exaggerated negative feedback response by the metyrapone administration may have accelerated the natural course of pituitary corticotropin adenoma and adrenal hyperplasia.
In summary, we reported a rare case of preclinical Cushing's disease characterized by massive bilateral adrenal hyperplasia, as a consequence of long-term metyrapone therapy.
